Susquehanna International Group, LLP Avadel Pharmaceuticals PLC Put Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Put Options

25 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 07, 2024	BUY	$12.55 - $17.22 $21.2 Million - $29.1 Million	1,690,400 Added 2666.25%	1,753,800 $29.6 Million
Q4 2023 Feb 14, 2024	SELL	$9.64 - $14.59 $42,416 - $64,196	-4,400 Reduced 6.49%	63,400 $895,000
Q3 2023 Nov 14, 2023	SELL	$10.3 - $15.99 $2.58 Million - $4.01 Million	-250,900 Reduced 78.73%	67,800 $698,000
Q2 2023 Aug 11, 2023	BUY	$8.48 - $16.48 $1.05 Million - $2.05 Million	124,300 Added 63.94%	318,700 $5.25 Million
Q1 2023 May 16, 2023	SELL	$6.41 - $9.95 $532,671 - $826,844	-83,100 Reduced 29.95%	194,400 $1.78 Million
Q4 2022 Feb 14, 2023	SELL	$5.02 - $10.0 $492,963 - $982,000	-98,200 Reduced 26.14%	277,500 $1.99 Million
Q3 2022 Nov 14, 2022	BUY	$2.57 - $7.31 $286,555 - $815,065	111,500 Added 42.2%	375,700 $1.88 Million
Q2 2022 Aug 15, 2022	BUY	$1.07 - $6.95 $108,498 - $704,730	101,400 Added 62.29%	264,200 $645,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $507,234 - $770,140	92,900 Added 132.9%	162,800 $1.11 Million
Q4 2021 Feb 14, 2022	SELL	$7.34 - $11.18 $386,818 - $589,186	-52,700 Reduced 42.99%	69,900 $565,000
Q3 2021 Nov 15, 2021	SELL	$6.49 - $9.91 $112,277 - $171,443	-17,300 Reduced 12.37%	122,600 $1.2 Million
Q2 2021 Aug 11, 2021	BUY	$6.73 - $9.05 $439,469 - $590,965	65,300 Added 87.53%	139,900 $942,000
Q1 2021 May 17, 2021	BUY	$6.61 - $10.07 $157,979 - $240,673	23,900 Added 47.14%	74,600 $674,000
Q4 2020 Feb 16, 2021	SELL	$5.03 - $7.95 $214,781 - $339,465	-42,700 Reduced 45.72%	50,700 $339,000
Q3 2020 Nov 16, 2020	BUY	$5.02 - $8.98 $207,827 - $371,772	41,400 Added 79.62%	93,400 $471,000
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $52,200 - $84,600	7,200 Added 16.07%	52,000 $420,000
Q1 2020 May 15, 2020	SELL	$4.06 - $10.64 $496,943 - $1.3 Million	-122,400 Reduced 73.21%	44,800 $356,000
Q4 2019 Feb 14, 2020	BUY	$3.34 - $7.7 $491,982 - $1.13 Million	147,300 Added 740.2%	167,200 $1.26 Million
Q3 2019 Nov 14, 2019	SELL	$1.92 - $4.47 $1,728 - $4,023	-900 Reduced 4.33%	19,900 $83,000
Q4 2018 Feb 14, 2019	SELL	$1.74 - $4.66 $38,280 - $102,520	-22,000 Reduced 51.4%	20,800 $54,000
Q3 2018 Nov 14, 2018	SELL	$4.08 - $7.14 $30,192 - $52,836	-7,400 Reduced 14.74%	42,800 $188,000
Q2 2018 Aug 14, 2018	SELL	$5.89 - $7.78 $164,331 - $217,062	-27,900 Reduced 35.72%	50,200 $308,000
Q1 2018 May 15, 2018	BUY	$6.76 - $11.7 $318,396 - $551,070	47,100 Added 151.94%	78,100 $569,000
Q4 2017 Feb 14, 2018	BUY	$8.03 - $11.25 $128,479 - $180,000	16,000 Added 106.67%	31,000 $254,000
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $125,250 - $157,500	15,000	15,000 $158,000

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $662M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account